Hong Kong Stock Movement: Partnering with Stanford to Accelerate AI Drug Research, XTALPI Soars 12.62% Leading the Biotechnology Sector

Hong Kong Stock Movement

XTALPI rose 12.62%. Based on recent key news:

1. On September 18, XTALPI announced that its wholly-owned subsidiary LCC Technologies has reached a drug discovery cooperation agreement with Stanford University. This collaboration combines Stanford's disease biology research with LCC's automated and AI-driven small molecule drug discovery platform to accelerate new drug development. This news drove the stock price up by 12.62%.

2. On September 18, XTALPI's stock price performed outstandingly in the Hang Seng Biotechnology Index, becoming the second largest gainer. The index rose by 1.6%, while XTALPI's stock price increased by 9.9%, reaching HKD 7.58.

3. On September 18, the cooperation agreement of XTALPI was seen as consolidating its position in the AI+ automated drug discovery field and providing opportunities to participate in early collaboration projects, further driving up the stock price. The biotechnology industry has been active recently, with significant capital inflows.

Stocks with High Trading Volume in the Industry

Insilico Medicine rose 9.12%. Based on recent key news:

1. On September 16, Insilico Medicine announced that its AI-driven drug Rentosertib completed its first patient enrollment and dosing at Peking Union Medical College Hospital and Shanghai Pulmonary Hospital. The trial aims to evaluate the efficacy and safety of Rentosertib in treating idiopathic pulmonary fibrosis. This progress marks a key step towards clinical validation and commercialization of the drug, driving up the stock price.

2. On September 18, Daiwa published a report stating that Insilico Medicine's revenue surged by 287.2% in the first half of this year, mainly driven by accelerated external licensing activities. The value of newly signed external licensing deals reached USD 7.3 billion, with a total cumulative value of external licensing deals amounting to USD 11 billion. Management reiterated the revenue guidance for 2026 remains unchanged at USD 150 million to USD 200 million, and expects the company to achieve adjusted non-IFRS net profit breakeven by 2026. These positive financial data and outlook boosted market confidence.

3. On September 18, KeyBanc analysts maintained a buy rating on Insilico Medicine and set a target price of HKD 86.50. The market generally considers the analyst consensus rating for Insilico Medicine to be a strong buy, with an average target price of HKD 79.88. This analyst rating further propelled the stock price upward. The Hong Kong innovative drug ETF Guangfa (513120) was actively traded.

King's Ray Biotechnology rose 4.46%. Based on recent key news:

1. On September 17, King's Ray Biotechnology reached a cooperation agreement with Eli Lilly to provide wet lab services, promoting AI drug discovery, with the stock price surging over 14%. Source: Zhitong Finance

2. On September 16, King's Ray completed a HKD 2.35 billion placement in the Hong Kong stock market to support AIDD business development and further expand wet lab verification capabilities. Source: Zhitong Finance On September 15th, JP Morgan increased its stake in Kingsray Holdings to 7.48%, demonstrating market confidence in its prospects. Source: Zhitong Finance. The AI drug discovery sector is growing rapidly, with significant capital inflows.

WuXi Biologics rose by 0.90%. Based on recent key news:

1. On September 16th, WuXi Biologics signed a contract in Wuxi to establish a commercial high-end manufacturing platform project. This project includes a new biopharmaceutical production line and supporting process development laboratory, covering cutting-edge biopharmaceutical categories such as monoclonal antibodies, promoting the company's layout in the biopharmaceutical field and enhancing market competitiveness.

2. On September 16th, WuXi Biologics was selected as a member of the 2026 ESG 50 list by Forbes China, recognized for its outstanding performance in sustainable development and ESG digital innovation, enhancing the company's reputation among investors.

3. On September 15th, WuXi Biologics recorded a large cross-trade transaction with a transaction amount of 43.99 million yuan, indicating ongoing market attention and active trading of the stock. WuXi Biologics continues to expand in the biopharmaceutical field.

Stocks ranked among the top in industry market capitalization

WuXi AppTec rose by 1.41%. Based on recent key news:

1. On September 17th, the Hong Kong stock market saw a collective rise in CRO concept stocks, with WuXi AppTec rising over 2%. Novo Nordisk's collaboration with Anthropic to utilize AI models to support drug development has boosted market confidence in CRO research efficiency, driving stock prices up. Source: Daily Economic News.

2. On September 16th, WuXi AppTec completed the conversion of convertible bonds, issuing an additional 543,200 H shares. This move increased market liquidity and may have a positive impact on stock prices. Source: Zhitong Finance.

3. On September 15th, global biotech financing has recovered, and WuXi AppTec's layout in the TIDES field has enhanced market confidence in its long-term growth potential. Source: Zhitong Finance. The pharmaceutical sector is active, with innovative drugs accelerating their international expansion